What happens if we get approval or limited approval. Price goes up, but how much? With institutional ownership around 85% and 20% short add to that 50,000 call options. What happens when the owners of those calls wants their 100 shares per contract? Will projected sales of drug really matter? Of course we need some form of approval first.
Sales, sales is what happens WHEN Heplisav gets even limited approval. It's a start and a revenue generator.
"Will projected sales of (the VACCINE) really matter?"
GSK would not have had Daum pull the shenanigans which he did if those Heplisav sales weren't going to matter. The FDA KNOWS and HAS STATED that there is a deficiency in seroprotective coverage with present vaccines and that Heplisav could fill that deficiency and offer improved coverage (with at least equal safety). More importantly, GSK also knows what the FDA knows and what it will mean for Engerix B......